相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
Jennifer L. Clarke et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
A Case of Radiation Recall Pneumonitis Induced by Erlotinib, Which Can be Related to High Plasma Concentration
Yosuke Togashi et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy
Rama Krishna Kancha et al.
CLINICAL CANCER RESEARCH (2009)
Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib
Tatsuya Katayama et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI
Hyeon Gyu Yi et al.
LUNG CANCER (2009)
Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene
Tatsuro Fukuhara et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
David M. Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells:: in vitro and in cancer patients
Jing Li et al.
INVESTIGATIONAL NEW DRUGS (2006)
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects
P Frohna et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Gefitinib is also active for carcinomatous meningitis in NSCLC
MK Kim et al.
LUNG CANCER (2005)
Leptomeningeal metastases from solid malignancy: a review
S Taillibert et al.
JOURNAL OF NEURO-ONCOLOGY (2005)
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen
JR Johnson et al.
CLINICAL CANCER RESEARCH (2005)
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp
Y Nagai et al.
CANCER RESEARCH (2005)
Single-dose clinical pharmacokinetic studies of gefitinib
HC Swaisland et al.
CLINICAL PHARMACOKINETICS (2005)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor
ER Lepper et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2003)
Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment -: Risk factors analysis
GL Ceresoli et al.
CANCER (2002)
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial
M Ronson et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
